Key Highlights

  • GeneDx shares are indicated up 7.66% in pre-market trading at $73.06, extending Monday's 7.59% after-hours gain.
  • Second-quarter revenue of $114.4 million, up 11.4% year over year, topped the $111.0 million consensus estimate.
  • Adjusted EPS of $0.01 beat the expected loss of $0.19 per share, a 105.26% beat, returning to adjusted profitability one quarter ahead of schedule.
  • The company reaffirmed full-year 2026 revenue guidance of $475 million to $490 million.
  • The results follow a sharp guidance cut in May tied to Fabric Genomics impairment issues that had triggered a securities class-action lawsuit.

What's Driving the Pre-Market Move

GeneDx Holdings (NASDAQ:WGS) shares are indicated up 7.66% in pre-market trading at $73.06, extending a 7.59% after-hours gain from Monday, after the company reported second-quarter results that beat Wall Street expectations across both revenue and earnings.

GeneDx is a Stamford, Connecticut-based genomics company and a global leader in rare disease diagnosis, providing genetic testing services with a primary focus on pediatric and rare disease diagnostics through whole exome and genome sequencing. The company holds approximately 35% to 40% of the U.S. pediatric whole exome sequencing market, leveraging a proprietary database of over 600,000 clinical exomes that delivers a diagnostic rate of approximately 38%, significantly above the industry average.

Second-quarter revenue was $114.4 million, up 11% year over year, with exome and genome revenue up 17% to $100.3 million on record volume of 30,785 tests, up 32% year over year. The company returned to profitability one quarter early with adjusted net income of $0.4 million, an $8.6 million improvement from the first quarter, and gross margin of 70%, up from 69% in the first quarter.

Blended average reimbursement rate per test was $3,258 in the second quarter, roughly flat sequentially, driven by genome mix moderating to 32% of insurance-based outpatient volume, down from roughly 40% in the first quarter, while outpatient genome collection rate stood at approximately 32%, flat versus the first quarter but down from 43% in the second quarter of 2025. Commercial genome coverage jumped to 87%, up from 47% last quarter, largely due to a Cigna and Carillon policy change, while commercial exome coverage reached 98%, with 39 states now covering exome and genome under Medicaid.

Guidance and Reassurance to Investors

Management reaffirmed full-year 2026 guidance of $475 million to $490 million in revenue, exome and genome volume growth of at least 30%, exome and genome revenue growth of at least 20%, gross margin of approximately 70%, and full-year profitability. Third-quarter guidance calls for revenue of $122 million to $124 million, exome and genome revenue of $110 million to $112 million, a blended ASP of approximately $3,300 per test, gross margin of approximately 70%, and adjusted net income of approximately $2 million.

The reaffirmed guidance provides reassurance to investors following a sharp guidance cut in May tied to Fabric Genomics impairment issues, which had triggered a securities class-action lawsuit with a lead-plaintiff deadline that expired the same day as this report. The company outlined four operational levers to improve reimbursement: mix management between exome and genome and reflex testing, payer coverage expansion, payer-specific workflows to reduce denials, and technology and AI investment in revenue cycle management, expecting collection rates to stay roughly flat in the third quarter with meaningful improvement in the fourth quarter and potentially reaching industry-standard levels of 70% by 2027.

Subsequent to quarter-end, GeneDx expanded its debt facility by $50 million and received an equity investment from Blackstone Life Sciences, bringing pro forma liquidity to approximately $188 million as of June 30. The company completed $25 million in annual cost actions, expects third-quarter cash burn of approximately $10 million with a return to cash flow generation in the fourth quarter, and maintained approximately 80% market share among geneticists, growing pediatric neurology share to approximately 50%.

GeneDx's market capitalization stood at $2.01 billion at Monday's close, with a trailing price-to-earnings ratio of 79.84. The stock's 52-week range spans $32.21 to $170.87.

Conclusion

GeneDx's second-quarter beat and reaffirmed full-year guidance appear to be restoring investor confidence following the disruptive Fabric Genomics impairment issue earlier this year. With the company back to adjusted profitability ahead of schedule and outlining a clear path toward improved reimbursement rates, the durability of today's gain will likely depend on continued execution against its reaffirmed targets.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.